Next Article in Journal
MSTN Regulatory Network in Mongolian Horse Muscle Satellite Cells Revealed with miRNA Interference Technologies
Next Article in Special Issue
Special Issue “Genetics and Epigenetics of Neuromuscular Diseases”
Previous Article in Journal
Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma
Previous Article in Special Issue
Homozygous Inversion on Chromosome 13 Involving SGCG Detected by Short Read Whole Genome Sequencing in a Patient Suffering from Limb-Girdle Muscular Dystrophy
 
 
Case Report
Peer-Review Record

Clinical, Biochemical, and Molecular Characterization of Two Families with Novel Mutations in the LDHA Gene (GSD XI)

Genes 2022, 13(10), 1835; https://doi.org/10.3390/genes13101835
by Pablo Serrano-Lorenzo 1,2, María Rabasa 3, Jesús Esteban 4, Irene Hidalgo Mayoral 1, Cristina Domínguez-González 1,2, Agustín Blanco-Echevarría 5, Rocío Garrido-Moraga 1, Alejandro Lucia 1,6, Alberto Blázquez 1, Juan C. Rubio 1, Carmen Palma-Milla 7, Joaquín Arenas 1,2 and Miguel A. Martín 1,2,*
Reviewer 1:
Reviewer 2:
Genes 2022, 13(10), 1835; https://doi.org/10.3390/genes13101835
Submission received: 16 September 2022 / Revised: 30 September 2022 / Accepted: 7 October 2022 / Published: 11 October 2022
(This article belongs to the Special Issue Genetics and Epigenetics of Neuromuscular Diseases)

Round 1

Reviewer 1 Report

In this paper, the authors do explore the genotype of two families suspected of GSD XI by TGS in the Spanish population. This is an interesting, straight forward small (small sample size) clinical study on GSD XI. I felt the paper made good results.

However, the method section can be shorter.

 

Also, please add your identified mutation into your table so the reviewers/readers can investigate and compare them.

Author Response

Dear reviewer,

Many thanks for your comments. We are pleased to satisfy your suggestions and queries:

- The method section can be shorter:

We have shortened the Methods section by summarizing the Clinical and methodological validation and PCR Amplification and Sanger Sequencing subsections.

- Also, please add your identified mutation into your table so the reviewers/readers can investigate and compare them.

We have added our patient’s data to Table 2.

Author Response File: Author Response.docx

Reviewer 2 Report

Thank you for asking me to review this manuscript, which describes two families with members affected with glycogen storage disease type XI, providing clinical, biochemical and molecular genetic analyses and reporting two novel pathogenic variants in the LDHA gene. The clinical phenotype described is consistent with that known already in this rare disorder.

As such this is an interesting case report for a rare disorder although no new insights are given beyond the novel mutations.

 

Minor points: 

Line 52 - there is a typo where "LDH" is given as "LHD"

Line 94 - it would be better to give the genes before the amino acid/ nucleotide variants.

Line 110 - what gene do these variants relate to?

Line 181 - give reference for the "1000 genomes database" or explain what this is.

Figure 2: can you include normal response curves?

Table 2: Define "NA".

 

Author Response

Dear reviewer,

Many thanks for your comments. We are pleased to satisfy your suggestions and queries:

- Line 52 - there is a typo where "LDH" is given as "LHD".

We have corrected the typo.

- Line 94 - it would be better to give the genes before the amino acid/ nucleotide variants.

We change the order of the genes and mutations so now the gene names are first presented.

- Line 110 - what gene do these variants relate to?

We have included the gene names to which the variants refers.

- Line 181 - give reference for the "1000 genomes database" or explain what this is.

We have changed it to “1000 Genomes Project database” to use the same name referenced in the methods section (line 129).

- Figure 2: can you include normal response curves?

An example of a normal response curve have been added to Figure 2.

- Table 2: Define "NA".

Now NA is defined on the foot of Table 2.

Author Response File: Author Response.docx

Back to TopTop